DrugRepV_0544 | Cepharanthine | Antiinflammatory and antineoplastic | Inflammatory disorders/Cancer | Ebola virus | EBOVBlaVP40 | NA | Fluorescence-based assay | Decrease (50 %) | NA | 26038505 |
DrugRepV_4728 | Chlorpromazine | Antiinflammatory and antineoplastic | Schizophrenia | Middle East respiratory syndrome coronavirus | Jordan | NA | Immunoflourescence assay | Decrease (50 %) | Approved | 29566060 |
DrugRepV_5085 | Chlorpromazine | Antiinflammatory and antineoplastic | Schizophrenia | Crimean-Congo hemorrhagic fever virus | 86-07 | NA | Plaque assay | Decrease (50 %) | Approved | 25796972 |
DrugRepV_5086 | Chlorpromazine | Antiinflammatory and antineoplastic | Schizophrenia | Crimean-Congo hemorrhagic fever virus | 87-07 | NA | Plaque assay | Decrease (50 %) | Approved | 25796972 |
DrugRepV_5088 | Chlorpromazine | Antiinflammatory and antineoplastic | Schizophrenia | Crimean-Congo hemorrhagic fever virus | 87-07 | NA | Plaque assay | Decrease (50 %) | Approved | 25796972 |
DrugRepV_5503 | Cepharanthine | Antiinflammatory and antineoplastic | Inflammatory disorders/Cancer | SARS Coronavirus-2 | GX_P2V/pangolin/2017/Guangxi | NA | qRT-PCR | Decrease (50 %) | NA | 32149769 |
DrugRepV_7558 | Chlorpromazine | Antiinflammatory and antineoplastic | Schizophrenia | SARS Coronavirus-2 | WA-1 strain - BEI ; NR-52286 | NA | Plaque assay / TCID50/ qRT-PCR | Decrease (50 %) | Approved | 32438446 |